FDA greenlights Revolution Medicines' pancreatic cancer gamechanger

The FDA has approved Revolution Medicines' RAS inhibitor daraxonrasib, branded Rasonque, for metastatic pancreatic cancer, marking a significant breakthrough in treating this hard-to-treat cancer. The drug showed unprecedented clinical results, doubling overall and progression-free survival and improving quality of life, and the company aims to expand its use and advance other RAS inhibitors.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it.